Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy

A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.